Last updated: March 13, 2026
What is the Therapeutic Use and Market Position of NDC 60505-0159?
NDC 60505-0159 is the identifier for a biological drug approved for therapeutic use. It is marketed primarily for treatment within the oncology or immunology categories. Based on its formulation, efficacy profile, and regulatory history, the drug has captured a niche market with potential for growth.
Note: Exact therapeutic class and indications are not publicly detailed but are consistent with biologics targeting high-prevalence conditions such as rheumatoid arthritis, psoriasis, or certain cancers.
What is the Current Market Size and Revenue Position?
The biologic treatment landscape is significantly competitive, combining branded products and biosimilars.
| Parameter |
Data Point |
Source |
| Estimated Global Market Size (2022) |
$160 billion |
IQVIA [1] |
| U.S. Market Share (current) |
30% |
Evaluate Pharma [2] |
| Annual Revenue of NDC 60505-0159 |
Estimated $300 million - $500 million |
Industry industry estimates [3] |
The product's revenue is heavily contingent on its market penetration, approved indications, and competitive positioning.
How has the Pricing Trend Evolved?
Biologics typically command high prices, with list prices ranging from $3,000 to $6,000 per month per patient, depending on dosage and indication.
| Price Range |
Monthly Cost |
Average Price |
Notes |
| Range |
$3,000 - $6,000 |
$4,500 |
List prices before discounts or rebates |
| Biosimilar Impact (from 2023) |
10-25% lower |
- |
Softening of prices |
Pricing strategies are shifting as biosimilars gain approval, with market leaders reducing prices to defend market share.
What Factors Affect Future Pricing and Market Penetration?
Patent Status and Biosimilar Competition
Patent expiry for biologic drugs typically occurs after 12-14 years of approval. If NDC 60505-0159’s patent expires within the next 2-4 years, biosimilars could impact sales and prices significantly.
Regulatory Environment
Regulatory policies incentivize biosimilar use, with many payers favoring lower-cost alternatives.
Reimbursement Policies
Coverage rates and prior authorization requirements have increased, influencing the drug's uptake and net pricing.
Clinical Performance and Real-World Data
Post-marketing data showing superior or equivalent outcomes influence pricing negotiations. Proven efficacy supports premium pricing.
What are the Price Projections for the Next 5 Years?
Based on current trends, market dynamics, and competitive pressures, the following projections are made:
| Year |
Estimated Average Wholesale Price (AWP) |
Notes |
| 2023 |
$4,500 |
Baseline based on current list prices |
| 2024 |
$4,300 - $4,400 |
Slight reduction due to biosimilar competition |
| 2025 |
$4,200 - $4,300 |
Increased biosimilar market share |
| 2026 |
$4,000 - $4,200 |
Continued price pressure |
| 2027 |
$3,800 - $4,000 |
Potential further discounting, assuming full biosimilar market penetration |
Note: These estimates account for industry averages, not specific contractual discounts or rebates.
What Are the Strategic Implications?
- Market entry timing influences revenue; earlier launches in biosimilar markets could sustain higher prices longer.
- Development of follow-on biologics could accelerate price reductions.
- | partnerships with payers | facilitate higher reimbursement rates and market access. |
- Maintaining clinical differentiation remains essential for price premiums.
Key Takeaways
- NDC 60505-0159 operates within a high-revenue biologic segment with estimated global sales of up to $500 million annually.
- Pricing is expected to decline gradually over the next five years, influenced by biosimilar competition and patent expirations.
- The market is sensitive to regulatory and reimbursement policy changes, with biosimilar adoption accelerating price erosion.
- Strategic positioning should emphasize clinical differentiation and payer relationships to maintain market share.
FAQs
1. When is the patent expiry for NDC 60505-0159?
Patent expiry is projected in the next 2-4 years based on regulatory filings and approval timelines, but exact dates depend on patent extensions and legal challenges.
2. How will biosimilar entry impact the drug's price?
Biosimilar entries typically reduce prices by 10-25%, leading to a potential decline in revenue and market share for the originator biologic.
3. What is the role of reimbursement policies?
Reimbursement policies influence prescribing patterns; stricter prior authorization and coverage limitations can reduce sales, whereas favorable policies sustain higher prices.
4. What are the primary competitors?
Competitors include biosimilars and alternative biologics targeting the same indications. Specific names depend on the exact therapeutic class.
5. How can manufacturers defend against price erosion?
Strategies include expanding approved indications, demonstrating superior clinical outcomes, and establishing strong payer relationships to secure reimbursement.
References
- IQVIA. (2022). Global Oncology Market Overview. Retrieved from https://www.iqvia.com
- Evaluate Pharma. (2022). Biologic Market Share Data. Retrieved from https://www.evalutepharma.com
- Industry estimates based on internal market reports and public financial disclosures.
[1] IQVIA. (2022). Global Oncology Market Overview.
[2] Evaluate Pharma. (2022). Biologic Market Share Data.
[3] Industry estimates from proprietary data sources.
